To the Editor:
When a patient is diagnosed with polymyalgia rheumatica (PMR), glucocorticoid (GC) therapy is mandatory, whatever the individual’s comorbidity. Strategies to reduce GC toxicity in high-risk patients include a lower starting GC dose than the usual 15–20 mg prednisolone, the association with methotrexate (MTX), the withdrawal of GC as soon as remission is achieved, a strict followup, and a pharmacological approach when appropriate (e.g., bisphosphonates to reduce fracture risk), along with general …
E-mail: mmazzant{at}int.med.unipi.it